Pharmaceutical industry
Op-Ed
The high cost of prescription drug price controls
Components of the Inflation Reduction Act have the very real potential of inflating drug prices with arbitrary price controls. Consumers will pay the price.
Originally published inThe Washington Times
Policy Brief
The Importance of Intellectual Property Protections in Fighting Pandemics
The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.